Steven DuBois, MD, MS
Director, Experimental Therapeutics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Associate Professor of Pediatrics, Harvard Medical School
Image
Steven DuBois, MD, MS
Director, Experimental Therapeutics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Associate Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Medical School
UCSF School of Medicine
2000
San Francisco
CA
Internship
Pediatrics
University of California, San Francisco, School of Medicine
2001
San Francisco
CA
Residency
Pediatrics
University of California, San Francisco, School of Medicine
2003
San Francisco
CA
Fellowship
Pediatric Hematology -Oncology
Boston Children's Hospital/Dana-Farber Cancer Institute
2007
Boston
MA
Certifications
American Board of Pediatrics (Hematology-Oncology)
Professional History
Dr. DuBois is a pediatric oncologist with a clinical focus on the care of children and young adults with solid cancers, including Ewing sarcoma and neuroblastoma. He is Director of Experimental Therapeutics for pediatric oncology and leads a team dedicated to developing new targeted agents for the treatment of childhood cancer.
Approach to Care
Dr. DuBois understands that each patient has unique needs and adapts his care to meet those needs. He believes in the importance of a team approach to the care of a young person with cancer, including patients and family members in shared medical decision making.
Publications
Preoperative Radiotherapy in Patients With Localized Ewing Sarcoma Enrolled on AEWS1031: A Report From the Children's Oncology Group. View Abstract
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors. View Abstract
A 2035 Clinical Research Vision and Roadmap for High-Risk Neuroblastoma. View Abstract
Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better. View Abstract
Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study. View Abstract
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors. View Abstract
Hypofractionated Palliative Radiotherapy for Relapsed and Refractory High-Risk Neuroblastoma. View Abstract
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. View Abstract
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors. View Abstract
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck. View Abstract
Racial and Ethnic Survival Disparities Among Children With High-Risk Neuroblastoma: A Children's Oncology Group Report. View Abstract
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors. View Abstract
Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children's Oncology Group. View Abstract
Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children's Oncology Group Bone Tumor Committee Consensus Statement. View Abstract
Targeted-Agent Continual Reassessment Method: A Novel Bayesian Enrichment Design for Phase I Trials of Molecularly Targeted Therapies. View Abstract
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823). View Abstract
Statistical Fragility of Findings From Randomized Phase 3 Trials in Pediatric Oncology. View Abstract
Poverty, race, ethnicity, and survival in pediatric nonmetastatic osteosarcoma: a Children's Oncology Group report. View Abstract
Response to induction chemotherapy modifies the effect of conventional prognostic factors in high-risk neuroblastoma: A report from the Children's Oncology Group. View Abstract
Consensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: A report from the National Ewing Sarcoma Tumor Board. View Abstract
Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field. View Abstract
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma. View Abstract
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3ß inhibitors in children and adolescents with cancer. View Abstract
Enrollment on upfront high-risk neuroblastoma trials by race, ethnicity, and poverty status: A report from the Children's Oncology Group. View Abstract
Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center. View Abstract
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma. View Abstract
Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma. View Abstract
Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials. View Abstract
Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma. View Abstract
Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma. View Abstract
Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031. View Abstract
Evaluation of prevalence and outcomes of serial tyrosine kinase inhibitor use in pediatric patients with advanced solid tumors. View Abstract
Clinical development of new drugs for adults and children with cancer, 2010-2020. View Abstract
Children's Oncology Group's 2023 blueprint for research: Bone tumors. View Abstract
Children's Oncology Group's 2023 blueprint for research: Neuroblastoma. View Abstract
Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. View Abstract
A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. View Abstract
Ewing Sarcoma Drug Therapy: Current Standard of Care and Emerging Agents. View Abstract
Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents. View Abstract
Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. View Abstract
Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. View Abstract
A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl). View Abstract
Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma. View Abstract
Systematic review of clinical drug development activities for neuroblastoma from 2011 to 2020. View Abstract
Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. View Abstract
Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. View Abstract
Early Termination of Oncology Clinical Trials in the United States. View Abstract
Analysis of Local Control Outcomes and Clinical Prognostic Factors in Localized Pelvic Ewing Sarcoma Patients Treated With Radiation Therapy: A Report From the Children's Oncology Group. View Abstract
Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group. View Abstract
NUT Carcinoma in Children and Adolescents: The Expert European Standard Clinical Practice Harmonized Recommendations. View Abstract
Reply to D.J. Benedetti et al. View Abstract
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. View Abstract
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. View Abstract
Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group. View Abstract
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. View Abstract
Report of the First International Symposium on NUT Carcinoma. View Abstract
Gamma Secretase Inhibition for a Child With Metastatic Glomus Tumor and Activated NOTCH1. View Abstract
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. View Abstract
Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy. View Abstract
68 Ga-DOTATATE PET and functional imaging in pediatric pheochromocytoma and paraganglioma. View Abstract
High-Risk Ewing Sarcoma: It Is Time to Break the Ceiling. View Abstract
High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes. View Abstract
ACCELERATE - Five years accelerating cancer drug development for children and adolescents. View Abstract
Reply to J.-G. Wang et al. View Abstract
Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. View Abstract
Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures. View Abstract
Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. View Abstract
Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy. View Abstract
Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. View Abstract
Belzutifan, a Potent HIF2a Inhibitor, in the Pacak-Zhuang Syndrome. View Abstract
The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. View Abstract
Anatomic patterns of relapse and progression following treatment with 131 I-MIBG in relapsed or refractory neuroblastoma. View Abstract
Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. View Abstract
Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. View Abstract
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. View Abstract
Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group. View Abstract
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. View Abstract
NUT Carcinoma Without Upfront Surgical Resection: A Case Report. View Abstract
Improving Outcomes in Children With High-Risk Neuroblastoma: The Role of Randomized Trials. View Abstract
Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors. View Abstract
Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives. View Abstract
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. View Abstract
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. View Abstract
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. View Abstract
Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors. View Abstract
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. View Abstract
A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: Opportunities for precision medicine. View Abstract
Opportunities and Challenges in Drug Development for Pediatric Cancers. View Abstract
Derivation and validation of risk groups in patients with osteosarcoma utilizing regression tree analysis. View Abstract
Stereotactic Body Radiation Therapy for Metastatic and Recurrent Solid Tumors in Children and Young Adults. View Abstract
Role of bone marrow biopsy for staging new patients with Ewing sarcoma: A systematic review. View Abstract
Advances and Challenges in Pediatric and Childhood Cancers. View Abstract
Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy. View Abstract
Landscape of phase 1 clinical trials for minors with cancer in the United States. View Abstract
The RACE to accelerate drug development for children with cancer. View Abstract
Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center. View Abstract
Trends in conditional survival and predictors of late death in neuroblastoma. View Abstract
The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. View Abstract
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. View Abstract
Population pharmacokinetics-pharmacodynamics of sunitinib in pediatric patients with solid tumors. View Abstract
Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. View Abstract
Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group. View Abstract
How to address challenges and opportunities in pediatric cancer drug development? View Abstract
Sponsorship of oncology clinical trials in the United States according to age of eligibility. View Abstract
DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. View Abstract
The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. View Abstract
Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. View Abstract
Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers. View Abstract
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. View Abstract
New approaches to therapeutic drug development for childhood cancers. View Abstract
Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics. View Abstract
Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. View Abstract
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. View Abstract
An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. View Abstract
Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma. View Abstract
A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. View Abstract
Author Correction: Reprogramming Escherichia coli for the production of prenylated indole diketopiperazine alkaloids. View Abstract
Second malignancies in patients treated for Ewing sarcoma: A systematic review. View Abstract
Clinical Impact of Tumor Mutational Burden in Neuroblastoma. View Abstract
Reprogramming Escherichia coli for the production of prenylated indole diketopiperazine alkaloids. View Abstract
Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. View Abstract
Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. View Abstract
Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). View Abstract
Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors. View Abstract
Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. View Abstract
Timing of first-in-child trials of FDA-approved oncology drugs. View Abstract
Ushering in the next generation of precision trials for pediatric cancer. View Abstract
Winning the RACE: Expanding pediatric cancer drug approvals. View Abstract
Duality of purpose: Participant and parent understanding of the purpose of genomic tumor profiling research among children and young adults with solid tumors. View Abstract
Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies. View Abstract
Risk stratification by somatic mutation burden in Ewing sarcoma. View Abstract
Neuroblastoma and Histone Demethylation. View Abstract
Genome-Informed Targeted Therapy for Osteosarcoma. View Abstract
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. View Abstract
Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. View Abstract
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. View Abstract
Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches. View Abstract
Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. View Abstract
Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma. View Abstract
Dual HDAC and PI3K Inhibition Abrogates NF?B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. View Abstract
Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis. View Abstract
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. View Abstract
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. View Abstract
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. View Abstract
Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. View Abstract
Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia. View Abstract
Pediatric NUT-midline carcinoma: Therapeutic success employing a sarcoma based multimodal approach. View Abstract
Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group. View Abstract
Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. View Abstract
Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma. View Abstract
Evaluation of the utility of 99m Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma. View Abstract
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. View Abstract
MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. View Abstract
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. View Abstract
Comparison of Clinical Features and Outcomes in Patients With Bilateral Versus Unilateral Adrenal Neuroblastoma. View Abstract
Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. View Abstract
Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma. View Abstract
A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors. View Abstract
Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. View Abstract
Assessment of Chemotherapy Response in Ewing Sarcoma: Response View Abstract
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. View Abstract
Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors. View Abstract
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. View Abstract
Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with (131)I-mIBG, a Targeted Radionuclide. View Abstract
Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. View Abstract
Reply: Is Extended Sedation Necessary for Young Children Receiving High-Dose (131) I-MIBG Therapy? View Abstract
Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. View Abstract
Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. View Abstract
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. View Abstract
Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. View Abstract
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. View Abstract
Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. View Abstract
Clinical Characteristics and Outcomes of Pediatric Patients with Desmoplastic Small Round Cell Tumor. View Abstract
Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. View Abstract
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. View Abstract
Conditional Survival and Predictors of Late Death in Patients With Ewing Sarcoma. View Abstract
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. View Abstract
Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. View Abstract
Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children's Oncology Group. View Abstract
Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. View Abstract
Extended Sedation With Continuous Midazolam or Dexmedetomidine Infusion for Young Children Receiving 131 I-MIBG Radiopharmaceutical Therapy for Advanced Neuroblastoma. View Abstract
Evaluation and Outcome of Central Nervous System Involvement in Pediatric Acute Lymphoblastic Leukemia in Dar es Salaam, Tanzania. View Abstract
Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG). View Abstract
Increased risk of second malignant neoplasms in adolescents and young adults with cancer. View Abstract
Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. View Abstract
Identification of Discrete Prognostic Groups in Ewing Sarcoma. View Abstract
Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG). View Abstract
Clinical features and outcomes of infants with Ewing sarcoma under 12 months of age. View Abstract
Patient-specific dosimetry using pretherapy [¹²4I]m-iodobenzylguanidine ([¹²4I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma. View Abstract
Second malignant neoplasms among children, adolescents and young adults with Wilms tumor. View Abstract
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. View Abstract
Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. View Abstract
Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group. View Abstract
Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium. View Abstract
Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group. View Abstract
Clinical Features and Outcomes Differ between Skeletal and Extraskeletal Osteosarcoma. View Abstract
Comparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma. View Abstract
Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. View Abstract
Secondary malignant neoplasms among children, adolescents, and young adults with osteosarcoma. View Abstract
Pediatric cancer type predicts infection rate, need for critical care intervention, and mortality in the pediatric intensive care unit. View Abstract
Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma. View Abstract
Current treatment and outcome for childhood acute leukemia in Tanzania. View Abstract
Comparison of Latino and non-Latino patients with Ewing sarcoma. View Abstract
Adverse impact of regional lymph node involvement in osteosarcoma. View Abstract
Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution. View Abstract
Acute changes in blood pressure in patients with neuroblastoma treated with ¹³¹I-metaiodobenzylguanidine (MIBG). View Abstract
131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma. View Abstract
Development of anaplastic Wilms tumor and subsequent relapse in a child with diaphanospondylodysostosis. View Abstract
131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. View Abstract
Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. View Abstract
Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis. View Abstract
Clinical features and outcomes in patients with secondary Ewing sarcoma. View Abstract
Evaluation of plasma annexin V levels in children and young adults with solid tumors. View Abstract
Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. View Abstract
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. View Abstract
Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG). View Abstract
Rates and appropriateness of antimicrobial prescribing at an academic children's hospital, 2007-2010. View Abstract
Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. View Abstract
Clinical features and outcomes in patients with Ewing sarcoma and regional lymph node involvement. View Abstract
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. View Abstract
Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma. View Abstract
Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. View Abstract
Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study. View Abstract
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. View Abstract
Phase I study of vincristine, irinotecan, and 131I-MIBG for patients with relapsed or refractory neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) study. View Abstract
Dosimetry, toxicity, and response in a phase IIa trial of no-carrier added iobenguane I-131 (nca-MIBG): A New Approach to Neuroblastoma Therapy (NANT) study. View Abstract
Surrogate biomarkers of antiangiogenesis in Children's Oncology Group (COG) phase I trials. View Abstract
Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. View Abstract
Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. View Abstract
Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. View Abstract
Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma. View Abstract
Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. View Abstract
Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation. View Abstract
Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. View Abstract
Osteosarcoma in children 5 years of age or younger at initial diagnosis. View Abstract
p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome. View Abstract
Ethnic and racial differences in patients with Ewing sarcoma. View Abstract
Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. View Abstract
Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow. View Abstract
Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors. View Abstract
Significance of tumor biology compared to metastatic pattern (INSS 4 versus 4s) and age for prognosis of neuroblastoma less than 18 months of age. View Abstract
Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy. View Abstract
Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma. View Abstract
Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. View Abstract
Ototoxicity in children treated for osteosarcoma. View Abstract
Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. View Abstract
Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. View Abstract
Late recurrence of ewing sarcoma during pregnancy: a report of 2 cases. View Abstract
Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. View Abstract
Early lymphocyte recovery in Ewing sarcoma. View Abstract
Desmoplastic small round cell tumor of the kidney in childhood. View Abstract
Markers of angiogenesis and clinical features in patients with sarcoma. View Abstract
Combined effects of granulocyte colony stimulating factor and radiation. View Abstract
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. View Abstract
Pediatric acute blastic natural killer cell leukemia. View Abstract
Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. View Abstract